IL314494A - Use of iptacopan for the treatment of lupus nephritis - Google Patents

Use of iptacopan for the treatment of lupus nephritis

Info

Publication number
IL314494A
IL314494A IL314494A IL31449424A IL314494A IL 314494 A IL314494 A IL 314494A IL 314494 A IL314494 A IL 314494A IL 31449424 A IL31449424 A IL 31449424A IL 314494 A IL314494 A IL 314494A
Authority
IL
Israel
Prior art keywords
iptacopan
lupus nephritis
treat lupus
treat
nephritis
Prior art date
Application number
IL314494A
Other languages
English (en)
Hebrew (he)
Inventor
Janina Linnik
Matthias Meier
Nicholas Webb
Original Assignee
Novartis Ag
Janina Linnik
Matthias Meier
Nicholas Webb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Janina Linnik, Matthias Meier, Nicholas Webb filed Critical Novartis Ag
Publication of IL314494A publication Critical patent/IL314494A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL314494A 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis IL314494A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
IL314494A true IL314494A (en) 2024-09-01

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314494A IL314494A (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
AU2023229221A1 (en) 2024-08-15
EP4486343A1 (en) 2025-01-08
JP2025507830A (ja) 2025-03-21
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
KR20240155291A (ko) 2024-10-28
MX2024010644A (es) 2024-09-06
CN118785906A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
IL284758A (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP4327587A4 (en) Radio frequency exposure mitigation
IL314494A (en) Use of iptacopan for the treatment of lupus nephritis
IL309232A (en) Urea derivatives which can be used to treat cancer
PL3988656T3 (pl) Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu
CR20200518A (es) Piridozinonas como inhibidores de parp7
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
EP3562486A4 (en) USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
IL313475A (en) Use of isoxazolinecarboxamide for sprout inhibition
IL287904A (en) Combination treatment of arthritic disease
EP4054774A4 (en) Organic waste treatment
EP4244818A4 (en) Disambiguation of poses
IL290321A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EP4103169A4 (en) METHOD FOR TREATING TAUOPATHY
IL271164A (en) Use of vibegron to treat overactive bladder
EP4284511C0 (en) AZAQUINOLINES AS CD38 INHIBITORS
EP4171502A4 (en) Use of oxygenated cholesterol sulfates for treating inflammatory conditions
IL285546A (en) Compounds and methods for reducing kcnt1 expression
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
IL285910A (en) Use of vibegron to treat overactive bladder
EP4305043A4 (en) Purification of sialooligosaccharides
IL307750A (en) Treatment of cutaneous lupus erythematous
EP3937946A4 (en) Use of gabaa receptor modulators for treatment of pain